Human Resources offers inclusive benefits to employees – Source

Building a more inclusive community at Colorado State University is a shared goal, and one that Human Resources embraces through offering inclusive benefits to our faculty and staff.

Employees may be unaware of medical benefits, leave options and wellness programs that are designed specifically to support all gender identities and people of color. While medical insurance benefits are largely dictated by the companies that provide them such as Anthem, Cigna and Kaiser the Human Resources office is pushing these partners to expand their resources.

We believe supporting a diversified workforce is not only the right thing to do, it also enhances productivity, creativity and the professional growth of all employees, said Robyn Fergus, vice president for Human Resources. By valuing the strengths that every employee brings to the table, we optimize on our strengths to the benefit of the university and the whole of our collective faculty and staff.

Examples of inclusive benefits available to employees entirely dependent upon the medical plan that they choose and other eligibility requirements include medical insurance coverage options for same or opposite gender legal, civil union and common-law spouses and domestic partners, and other dependents who are eligible, and coverage of hormone therapy. Before selecting a plan, you can consult with your insurance providing company to find a plan that is right for you and your family.

Same sex partners and spouses also qualify for paid parental leave, paid sick leave to care for the needs of a family member, and paid leave to volunteer at their childrens public schools.

All employees may also access the Employee Assistance Program. The programs partner, ComPsych, offers connections to inclusive mental health resources, including Servicios De La Raza, which provides behavioral health support that is culturally and linguistically responsive in English and Spanish, as well as programs such as Queer Asterisk, The Trevor Project, and the Black Mental Health Alliance.

The University strongly supports and advocates that the companies that provide medical benefits advance inclusive benefit offerings. Inclusive benefits improve employee health, prevent the onset of medical issues, and promote equity to help all of our employees know that the university values their health and well-being, said Teri Suhr, who oversees CSUs benefits programs as the Universitys chief total rewards officer.

For a listing of inclusive benefits, see hr.colostate.edu/inclusive-benefits/.

Benefits available to employees are dictated by their classification type, such as administrative professional or state classified, as well as the health plans they select, their full or part-time status, and other factors that define general eligibility for health benefits.

Continue reading here:

Human Resources offers inclusive benefits to employees - Source

Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial -…

- VISENs Phase 3 Trial achieved primary endpoint; pediatric growth hormone deficiency (GHD) patients treated with TransCon hGH demonstrated greater annualized height velocity at 52-weeks (p=0.0010) compared to patients treated with daily growth hormone

- These results demonstrate the ability of TransCon technology to deliver consistent and reproducible results for patients across a broad range of geographies and populations

COPENHAGEN, Denmark, May 23, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S ( ASND) announced today that results from VISEN Pharmaceuticals Phase 3 trial of once-weekly TransCon hGH in children with GHD in China demonstrated results that were consistent with the Ascendis Pharmas earlier multi-national Phase 3 trial. VISEN Pharmaceuticals Phase 3 trial achieved its primary endpoint, with pediatric GHD patients treated with once-weekly TransCon hGH demonstrating greater annualized height velocity at 52-weeks (p=0.0010) compared to patients treated with daily growth hormone. In both Ascendis Pharmas and VISEN Pharmaceuticals Phase 3 trials, TransCon hGH now approved in both the U.S. and EU as a once-weekly treatment for pediatric GHD demonstrated statistical non-inferiority and superiority on the primary endpoint with comparable safety and tolerability to daily growth hormone.

Ascendis Pharma congratulates VISEN Pharmaceuticals for successfully completing its first Phase 3 clinical trial of a TransCon product candidate in China, said Jan Mikkelsen, Ascendis Pharmas President and Chief Executive Officer. These results demonstrate the ability of TransCon technology to deliver consistent and reproducible results for patients across a broad range of geographies and populations.

Results of the Phase 3 trial of TransCon hGH in China were reported by VISEN Pharmaceuticals, whose press release can be viewed on http://www.visenpharma.com.

About Pediatric Growth Hormone DeficiencyPediatric GHD is a serious orphan disease characterized by short stature and metabolic abnormalities that affect overall physical and mental health. In GHD, the pituitary gland does not produce sufficient growth hormone, which is important not only for height but also for optimal bone, heart, muscle, and brain development.

About TransCon TechnologyTransCon refers to transient conjugation. The proprietary TransCon platform is an innovative technology to create new therapies that optimize therapeutic effect, including efficacy, safety and dosing frequency. TransCon molecules have three components: an unmodified parent drug, an inert carrier that protects it, and a linker that temporarily binds the two. When bound, the carrier inactivates and shields the parent drug from clearance. When injected into the body, physiologic pH and temperature conditions initiate the release of the active, unmodified parent drug in a predictable release manner. Because the parent drug is unmodified, its original mode of action is expected to be maintained. TransCon technology can be applied broadly to a protein, peptide or small molecule in multiple therapeutic areas, and can be used systemically or locally.

About Ascendis Pharma A/SAscendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients lives. Guided by its core values of patients, science and passion, the company uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Heidelberg and Berlin, Germany; Palo Alto and Redwood City, California; and Princeton, New Jersey. Please visit http://www.ascendispharma.com to learn more.

Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis ability to apply its platform technology to build a leading, fully integrated biopharma company, and (ii) Ascendis use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers and distributors to supply TransCon hGH, the SKYTROFA Auto-Injector and other study drug for commercial sales in the U.S. and clinical studies; unforeseen safety or efficacy results in its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to commercialization of lonapegsomatropin-tcgd in the U.S., the co-pay program, and the further development of TransCon hGH, expenses related to the development and potential commercialization of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs, selling, general and administrative expenses, other research and development expenses and Ascendis business generally; delays in the development of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; Ascendis ability to obtain additional funding, if needed, to support its business activities and the effects on its business from the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis business in general, see Ascendis Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on March 2, 2022 and Ascendis other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and SKYTROFA are trademarks owned by the Ascendis Pharma Group. May 2022 Ascendis Pharma A/S.

Originally posted here:

Positive Results from VISEN's Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma's Phase 3 Height Trial -...

Swole Is The Goal: ARod’s Girlfriend Gets A Pump In On Their Italian Vacation – OutKick

Content machines ARod and girlfriend Kathryne Padgett were at it again Monday with the slugger behind the camera as his fitness model girlfriend got swole and then jumped into ocean waters in some undisclosed location.

If youve been on a vacation of your own and havent been following along, ARod rented out a ship for yet another summer vacation that includes Padgett, former NFL wide receiver Eric Decker and his wife/singer Jessie James Decker. Others have joined the fray over the last week, but these are the main actors who have been pumping out content for the tabloids.

Padgett, who got off to a slow start this year as the girlfriend that ARod wouldnt admit was his girlfriend, seems to be full bore now as theres no longer a cat-and-mouse game over how serious ARod is with this relationship.

Shes officially living the yacht life with ARod and that means she can just be herself. If she needs to get the shoulders swole, theres a gym for that on this yacht. If she needs to get a cardio swim in with her shoulder press supersets, she just jumps off the yacht.

Did you see this type of performance out of J Lo? Hell no you didnt. She was too busy bitching and moaning as if life is just so damn hard when youre worth nine figures. Spare me, darling.

Thats why this Padgett thing seems to be working for ARod. Hes 46 and clearly not ready to get old. Padgett is reportedly 25!

Youre damn right shes full of energy.

Lets be real here for a minute. ARod should be on whatever he needs to be on to keep up with this machine. Should he be injecting that crap Frank Thomas is pimping on Bally Sports or late-night on the Golf Channel? Hell yes, inject it straight into ARods veins.

HGH? Hell yeah, give it to me!

Blood doping like Lance Armstrong who magically rode up those mountains like he was possessed?

Oh yeah, give me that crap too! Give it all to me.

If I have ARods money and an all-gas, no brake 25-year-old fitness model I am on the best stuff that Jeff Bezos can get his hands on.

Read the original:

Swole Is The Goal: ARod's Girlfriend Gets A Pump In On Their Italian Vacation - OutKick

Crinetics: Late-Stage Acromegaly Disease Studies Will Be Inflection Point (NASDAQ:CRNX) – Seeking Alpha

D-Keine/E+ via Getty Images

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a great speculative biotech play to look into. That's because it is expected that it will release results from two phase 3 studies under the PATHFNDR program in 2023. Both studies, known as PATHFNDR-1 and PATHFNDR-2, are using paltusotine for the treatment of patients with Acromegaly. One study is switching patients from injectable standard of care (SOC) treatments and the other is targeting untreated patients. Both of these randomized trials will be important, because they will be needed for the company to be able to file a New Drug Application (NDA) to the FDA for approval thereafter. A prior phase 2 study, known as ACROBAT, showed that patients were able to maintain hormone suppression even after switching from SOC injections to paltusotine.

Paltusotine is also being explored for use in treating patients with neuroendocrine tumors and carcinoid syndrome in phase 2 testing. Another important program would be the use of CRN04777 which was shown to be safe/tolerable in patients with congenital hyperinsulinism in a phase 1 study. Crinetics is in the process of initiating a phase 2 study using CRN04777 for this patient population in the 2nd half of 2022. With proof of concept established in phase 2 for paltusotine for Acromegaly, plus a major readout from a late-stage study for this program in 2023, these are the reasons why I believe this biotech is a great speculative biotech play to look into.

Paltusotine is being developed for the treatment of patients with Acromegaly. This is a differentiated treatment option for patients, because it is being developed as an oral treatment. Current standard of care (SOC) treatment options used are injections. Acromegaly is a type of hormonal disorder that occurs when your pituitary gland produces too much growth hormone during adulthood. What happens is that bones and other parts of the body become enlarged. The enlarged parts of the body that are possible for those who have Acromegaly are:

In Adulthood though, height is something that doesn't change for someone who has Acromegaly. It is a rare disorder in that there are fewer than 20,000 U.S. cases per year. The key is that these patients are able to bring growth hormone and IGF-1 levels to a normal level. If this can be accomplished only then can these patients have a normal life expectancy.

The thing is that this program has come a long way. Why is that? Well, that's because a phase 1 study using paltusotine was initiated back in 2018. Since then, it has really done well to advance the use of this drug for the treatment of patients with Acromegaly. After that, it has been able to advance two separate phase 2 studies recruiting patients with Acromegaly.

These two studies are the phase 2 ACROBAT Edge and ACROBAT Evolve studies. Any patient who finished either of these studies were then enrolled into the phase 2 Open-Label Extension (OLE) study known as ACROBAT Advance. The good thing here is that Crinetics released some positive long-term data from this particular OLE study back on November 8, 2021. It was shown that with a cut off date of August 31, 2021 41 patients had gone through and received paltusotine for a total of 51 weeks.

A really good thing about this study is that only 4 patients ended up discontinuing from the study. The main takeaway that you should know about this study is that patients taking paltusotine ended up achieving lower median serum insulin-like growth factor-1 ((IGF-1)) levels compared to the washout period. A washout period is where patients take no drug whatsoever. This signifies that the drug was able to do a good job at lowering IGF-1 levels. Not only that, but it was able to maintain such levels for an extended period of time similar to that which was achieved on prior SRL therapy for up to 51 weeks.

There are two important things to explain here. The first of which is that SRL therapy is a standard of care (SOC) treatment option for these patients with Acromegaly. SRL stands for somatostatin-receptor ligand and is responsible for slowing down the production of hormones, especially the growth hormone and serotonin. While it works well, there are a few issues with it. They are:

Secondly, the main problem with Acromegaly goes to what I stated above in the definition of it. That is, if a therapy can fully lower serum insulin-like growth factor-1 ((IGF-1)) levels to normal, then these patients can be treated properly. It's hard to say whether or not the drug will be successful, but it is important to note that about 41 out of 49 (84%) of the eligible patients decided to remain in the ACROBAT Advance study.

With achieving such great success in the IGF-1 biomarker data from several phase 2 studies with paltusotine in treating patients with Acromegaly, it has already been able to advance a phase 3 program known as PATHFNDR. It had dosed the first patient in the phase 3 PATHFNDR-1 in June of 2021. This late-stage study is expected to enroll up to a total of 52 patients with Acromegaly who are at the time of study entry biochemically controlled.

What does that mean? It means that these patients have insulin-like growth factor-1 ((IGF-1)) 1.0x upper limit of normal (ULN). They achieve this while on other standard of care (SOC) treatment options like octreotide or lanreotide (synthetic version of stomatostatin) depot monotherapy. Patients for this phase 3 PATHFNDR-1 study are randomized to receive 1:1 to receive once daily oral paltusotine or placebo for a total of 9 months. The main thing to note here is that these patients are switching off of SOC injection treatment over to paltusotine. The primary endpoint for the study is going to be the proportion of patients who will be biochemically controlled during at least weeks 32 to 36. The only major downside at the moment for this particular program is that results from this late-stage study with paltusotine are not expected to be released until 2023. There is also a second phase 3 randomized double-blind placebo-controlled study known as PATHFNDR-2. This study is similar to the other late-stage study, but instead is treating patents who have not been treated. In essence, there are two criteria for recruiting in this late-stage study. These two stipulations are:

The primary endpoint will be the average IGF-1 1.0x ULN at weeks 22 to 24. Again, this will be the use of paltusotine compared to placebo. This is another study, which is expected to have data released in 2023.

Hopefully paltusotine does well in these studies for Acromegaly. However, things are looking good in that Crinetics has already been able to establish a partnership with a Japanese pharmaceutical company by the name of Sanwa Kagaku Kenkyusho Co., Ltd. (Known as "Sanwa") for paltusotine. Crinetics received $13 million as an upfront payment and then also may be eligible to earn milestone payments relating to certain development, regulatory and commercial goals being met. If paltusotine achieves marketing approval in Japan, then it will also be able to receive tiered royalties on net product sales. Sanwa will have the right to develop and commercialize the drug for Acromegaly/neuroendocrine tumors in Japan. That's okay though, because it will be responsible for all costs of every single study done in Japan for it. This means that Crinetics won't have to worry about funding or spending money to run these studies in that specific territory. Not only that, but it still retains rights for paltusotine outside of Japan. What does this do? Well, it provides the ability for it to attempt to make another partnership for the drug in another territory besides Japan. If that doesn't happen, then it retains full rights for the drug in the rest of the territories.

According to the 10-Q SEC Filing, Crinetics Pharmaceuticals had cash, cash equivalents and investments of $319.7 million as of March 31, 2022. This is a lot of cash on hand, however, there is one important thing to consider here and that is that this amount does not include the most recent cash offering it had enacted in April of 2022. That is when it sold a total of 5,625,563 shares of its common stock at a price of $22.22 per share. It received roughly $125 million in gross proceeds from the common stock offering. It believes that it has enough cash on hand to fund its operations into the 2nd half of 2024. This means I don't anticipate another cash raise for quite some time. I believe that if it does enact another cash raise it will choose to do so by at least mid-2023 or thereafter. The only way it would want to raise earlier than expected is if market conditions worsen even further or it has a strategic transaction it wants to accomplish. Other than both of these situations, it won't need to raise cash for quite some time.

There are a few risks that investors should be aware of before investing in Crinetics Pharmaceuticals. The first risk involves the PATHFNDR program itself. While it achieved success with the primary endpoint using paltusotine in Acromegaly in a prior phase 2 study, there is no guarantee that the same will be done in either one of the two ongoing PATHFNDR studies. Results from either one of these studies won't be known until 2023.

The second risk involves the use of CRN04777 for congenital hyperinsulinism. A phase 1 study completed the safety portion and was shown to be tolerable. There was also some proof of concept evidence of being able to achieve dose-dependent suppression of glucose or sulfonylurea-induced insulin secretion as well. The next step is for the biotech to speak to regulators and initiate a phase 2 study using CRN04777 for congenital hyperinsulinism to confirm efficacy. This mid-stage study is expected to start in the 2nd half of 2022. One caveat from its main program is that paltusotine is also being developed to treat patients with neuroendocrine tumors as well in a phase 2 study. This provides another shot on goal, just in case the drug doesn't succeed in the two ongoing PATHFINDR studies for Acromegaly.

The final conclusion is that Crinetics Pharmaceuticals is a great speculative biotech play to look into. That's because it has already established proof of concept of being able to achieve normal hormone and IGF-1 levels in a phase 2 study. The two ongoing PATHFNDR studies using paltusotine for patients with Acromegaly may ultimately prove this finding.

At least the biotech has been advancing its pipeline providing additional shots on goal. Paltusotine is also being used to treat patients with neuroendocrine tumors as well. It has already done some leg work in showing that CRN04777 is safe and provides dose-dependent suppression of glucose or sulfonylurea-induced insulin secretion in a phase 1 study. A phase 2 study using this drug for the treatment of patients with congenital hyperinsulinism is expected to start in the 2nd half of 2022. It has even been able to spin out a company known as Radionetics oncology, which will be focused on advancing nonpeptide precision radiotherapeutics for the treatment of patients with cancer. This company was spun out from Crinetics nonpeptide platform.

Another drug in Crinetics pipeline is CRN04894, which is an ACTH antagonist. It is being developed to treat patients with Congenital adrenal hyperplasia and Cushing's Disease. Based on proof of concept established in phase 2 for paltusotine in Acromegaly, plus many other drugs being advanced in the pipeline for additional shots on goal, these are the reasons why I believe this is worth a look as a speculative biotech play. The two trial readouts from the phase 3 PATHFNDR studies provide major inflection points for Crinetics.

Originally posted here:

Crinetics: Late-Stage Acromegaly Disease Studies Will Be Inflection Point (NASDAQ:CRNX) - Seeking Alpha

Joe Rogan Is On Steroids – Gets High And Reveals What He Takes To Maintain Physique – The Overtimer

While featuring in one podcast, the UFC color commentator and podcaster Joe Rogan reveals what everybody wants to know. He reveals what he takes to maintain his physique.

Joe Rogan is a true celebrity. His podcast is so popular, that he has a worldwide reach. People around the world listen to it and eagerly await the next episodes. The reason his podcast The Joe Rogan Experience is so popular is because of the complex topics he deciphers.

Andrew Schulz is a comedian and also a fellow podcaster. He is a friend of Joe Rogan and frequently guests on his podcast. However, now, it was time for Joe to return the favor. Rogan guests on Schulzs podcast where the duo elaborates on various topics, among which the supplements and restricted substances that Rogan uses on a regular basis. Both of them get high while speaking and open up about some topics that Rogan usually doesnt speak about.

Rogan has a broad knowledge of supplements. He first mentions the Alpha Brain Black Label supplement, which is a supplement used for enhancing the cognitive function of the brain. It doesnt take much for Schulz to ask the question directly.

Joe, whats everything you take? he asks.

The big results come from testosterone replacement, so theres that, and then there are peptides that increase your bodys ability to grow hormones like growth hormones and IGF-1, Insulin-like growth factor 1 and all. Rogan replies.

Theres BPC-157, ipamorelin, thymosin. What these things do is they help your body produce the hormones that it should have when youre younger, and your body works better. he adds.

And this is not the first time that Rogan speaks about his hormone use. In past episodes of his podcast, he hints that he does take testosterone-based hormones. Now, he decides to get into details and explain more about his routines. He reveals that hormones make him feel younger, feel more powerful, and finally, they boost his strength and durability massively.

Joe Rogan believes that regular exercise and regular supplementation with multivitamins can help you greatly with your overall health and looks.

Regular exercise is the biggest thing. If theres ever one thing that someone can do to stop aging is to lift weights and dont stop. Dont lift weights for vanity. Do it because you want to keep your tissue. Age is like a little demon that is slowly robbing you of your tissue. Your ability to walk upstairs, your ability to open up jars, your ability to open the car door when its frozen. The only way to stave that off is weight lifting. he says on Schultzs podcast.

He reveals that the secret is not to lift as heavy as you can and exhaust yourself to the maximum. The thing is that you need to train regularly. No excuses, and no pauses. Regular work does the deed.

I cannot agree more on this with Rogan. Regular exercise is half of your health. The other half is a healthy diet. Once you have these two aligned success is inevitable.

Steroids are a shortcut to results in fitness and any other sport for the matter. However, while using them can have many pros, the cons are so bad, that once you know them, the chances that youll decide to take roids is close to none.

So, exercise regularly, eat healthily and everything else will fall into place.

Read the original post:

Joe Rogan Is On Steroids - Gets High And Reveals What He Takes To Maintain Physique - The Overtimer

Short Interest in Ipsen S.A. (OTCMKTS:IPSEY) Expands By 80.0% – Defense World

Ipsen S.A. (OTCMKTS:IPSEY Get Rating) was the target of a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling 900 shares, a growth of 80.0% from the May 15th total of 500 shares. Based on an average trading volume of 1,200 shares, the days-to-cover ratio is presently 0.8 days.

Shares of IPSEY opened at $24.14 on Monday. The stock has a 50 day moving average price of $27.14 and a two-hundred day moving average price of $26.50. Ipsen has a 52 week low of $21.71 and a 52 week high of $32.51.

The business also recently disclosed a dividend, which was paid on Thursday, June 9th. Shareholders of record on Wednesday, June 1st were issued a dividend of $0.2269 per share. This represents a yield of 0.88%. The ex-dividend date was Tuesday, May 31st.

About Ipsen (Get Rating)

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents.

Featured Articles

Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.

More:

Short Interest in Ipsen S.A. (OTCMKTS:IPSEY) Expands By 80.0% - Defense World

Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program – Montreal Gazette

Breadcrumb Trail Links

Author of the article:

Company advancing AIM Biologicals development program as a potential therapeutic treatment option for neuromyelitisopticaspectrum disorder (NMOSD)

Positive results presented at the 13thInternational Congress on Autoimmunity being held in Athens, Greece

Preliminary data with mouse 2D2 models of spontaneousautoimmune encephalomyelitis (EAE) indicate that mouse-adapted AIM Biologicals may reduce optic neuritis, loss of inner nuclear layer neurons and EAE symptoms

This advertisement has not loaded yet, but your article continues below.

TORONTO, ONTARIO, June 13, 2022 (GLOBE NEWSWIRE) Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (Aeterna or the Company), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced its Autoimmunity Modifying (AIM) Biologicals program has achieved pre-clinical proof-of-concept for the potential treatment of neuromyelitis optica spectrum disorder (NMOSD) (also known as Devic disease), a chronic autoimmune disorder of the brain and spinal cord dominated by inflammation of the optic nerve and spinal cord and which can be fatal in approximately 30% of patients within five years of diagnosis. These findings were presented at the 13th International Congress on Autoimmunity being held June 10-13, 2022 in Athens, Greece.

This advertisement has not loaded yet, but your article continues below.

The abstract presented at the Congress, titled Antigen presentation on MHC class Ibrelatedmolecules induces Aquaporin-4-specific regulatory T cells in PBMC and prevents experimental autoimmune encephalomyelitis in mice, was presented in a poster format and as an oral presentation by Aeternas research collaborator, Valentin Bruttel, PhD, Senior Researcher, Department of Obstetrics and Gynecology, School of Medicine, University of Wuerzburg (the University).

There remains strong unmet medical need to provide treatment options for patients diagnosed with NMOSD, a rare but potentially devastating autoimmune condition. Given the severe impact NMOSD can have on people, we are very encouraged by the proof-of concept our AIM Biologicals program has demonstrated in both in vitro and mouse models, said Dr. Klaus Paulini, Chief Executive Officer of Aeterna. We are grateful for the collaborative work being done with Dr. Bruttel, Prof. Wischhusen and their team, and we look forward to continue further developing Aeternas AIM Biologicals for the potential treatment of NMOSD.

This advertisement has not loaded yet, but your article continues below.

Aquaporin-4 (AQP-4) is the autoimmune antigen implicated in neuromyelitis optica (NMO), a demyelinating and inflammatory autoimmune disorder of the central nervous system (CNS). AIM Biologicals are based on a mechanism that is physiologically important for feto-maternal immune tolerance during pregnancy. These new biomolecules utilize the 3 domain of the human MHC class Ib molecule HLA-G to inhibit antigen-specific T cells via the human ILT-2 or the murine PIRB receptor. As part of Aeternas ongoing pre-clinical studies in collaboration with the University, researchers at the University generated fusion proteins comprising an AQP-4-derived antigenic peptide, MHC class I 1-2 antigen presenting domains, the HLA-G 3 domain and b2-microglobulin to investigate whether these novel single-chain biomolecules can induce antigen-specific tolerance towards presented AQP-4 and other neuroinflammatory peptide antigens. Various AIM Biologicals were then tested and shown to induce antigen-specific regulatory T cells (Treg) in vitro and to inhibit CD8+ driven experimental autoimmune encephalomyelitis (EAE) models and optic neuritis in 2D2 mice in vivo.

This advertisement has not loaded yet, but your article continues below.

We are very pleased with these pre-clinical proof-of-concept results which help to inform our research moving forward to define a development candidate. As demonstrated in these pre-clinical studies, we believe that Aquaporin-4-specific AIM Biologicals have the potential to provide targeted immunosuppression in NMOSD. We look forward to advancing this important program with our exclusive licensee, Aeterna, to potentially meet an indication where there remains unmet medical need, added Dr. Bruttel, who has just received the audience prize and the German innovation award at the recent German Biotechnology Days 2022.

Summary of Key Highlights

This advertisement has not loaded yet, but your article continues below.

The poster can be accessed on the Publications page of the Companys website.

About Neuromyelitis Optica Spectrum Disorder (NMOSD)

NMOSD is an antibody mediated inflammatory central nervous system (CNS) disorder that affects about one per 100,000 population per year. NMOSD, also known as Devics disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and of the spinal cord (myelitis). Typical symptoms include vision loss, muscle spasms, paraparesis, and incontinence. If left untreated, 50% of individuals with NMOSD may become wheelchair bound and blind, and 30% may have died within five years after the first attack. The water channel protein AQP4 is widely expressed in the brain, spinal cord, and optic nerves. Auto-antibodies directed against AQP4 play an important role in the pathogenesis of NMOSD.

This advertisement has not loaded yet, but your article continues below.

Currently there are only three approved medications available for the treatment of NMOSD, all with very high annual treatment costs and the risk of the patient contracting serious infections. Therefore, the Company believes there remains a strong medical need to offer new therapeutic options to the patients.

In the U.S. and Europe there are currently approximately 10,000 to 15,000 patients living with NMOSD. Of these the AQP4 antibody seropositive patients who represent about 80% of the NMOSD population are the targeted patients for a potential therapy based on the AIM Biologicals technology.

About AIM Biologicals

AIM Biologicals are targeted, highly specific autoimmunity modifying therapeutics. This platform technology utilizes a mechanism that is physiologically required for feto-maternal immune tolerance during pregnancy. Despite 50% paternal antigens, the maternal immune system tolerates a fetus, while protection against pathogens is retained. This requires selective tolerance induction against fetal antigens. During pregnancy, this goes along with an amelioration of autoimmune diseases.

This advertisement has not loaded yet, but your article continues below.

AIM Biologicals utilize a novel technique which is based on the presentation of antigens on immunosuppressive MHC class I molecules to selectively and efficiently induce antigen-specific tolerance. Based on this mechanism, targeted immunomodulatory therapeutics are designed as optimized soluble molecules and adapted to selectively induce tolerance to various autoantigens. Pre-clinical studies conducted thus far indicate that tolerance induction may be achieved via selective elimination of antigen-specific immune effector cells and via induction of antigen-specific regulatory T cells from nave T cells.

For the potential treatment of NMOSD, AIM Biologicals presenting a specific antigen derived from the water channel protein aquaporin-4 (AQP4) loaded onto a soluble immunoregulatory HLA-G protein has the potential to selectively induce immunological tolerance in the central nervous system. AIM Biologicals thus have the potential to become highly specific and effective yet not personalized treatment options for NMOSD.

This advertisement has not loaded yet, but your article continues below.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Companys lead product, macimorelin (Macrilen; Ghryvelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need, in collaboration with Novo Nordisk.

Aeterna Zentaris is dedicated to the development of therapeutic assets and has recently taken steps to establish a growing pre-clinical pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinsons disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou Gehrigs disease). Additionally, the Company is developing an oral prophylactic bacterial vaccine against SARS-CoV-2 (COVID-19) and Chlamydiatrachomatis.

This advertisement has not loaded yet, but your article continues below.

For more information, please visit http://www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains statements that may constitute forward-looking statements within the meaning of U.S. and Canadian securities legislation and regulations and such statements are made pursuant to the safe-harbor provision of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements are frequently, but not always, identified by words such as expects, anticipates, believes, intends, potential, possible, and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking statements in this press release include, but are not limited to, those relating to: expectations regarding the potential of AIM Biologicals, to the potential to provide targeted immunosuppression, to be a highly specific and effective treatment for NMOSD and the Companys ability to conduct pre-clinical research to identify and characterize an AIM Biologicals-based development candidate for the treatment of NMOSD.

This advertisement has not loaded yet, but your article continues below.

Forward-looking statements involve known and unknown risks and uncertainties, and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks and uncertainties include, among others, results from ongoing or planned pre-clinical studies of our products under development may not be successful or may not support advancing the product to human clinical trials; our ability to raise capital and obtain financing to continue our currently planned operations; our now heavy dependence on the success of Macrilen (macimorelin) and related out-licensing arrangements and the continued availability of funds and resources to successfully commercialize the product, including our heavy reliance on the success of the license agreement and the amended license agreement (collectively the Novo Amended License Agreement); the global instability due to the global pandemic of COVID-19 and the war in the Ukraine and the resulting geopolitical instability, and its unknown potential effect on our planned operations; our ability to enter into out-licensing, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; and our ability to continue to list our common shares on the NASDAQ. Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties, including those risks discussed in our Annual Report on Form 20-F and annual information form, under the caption Risk Factors. Given the uncertainties and risk factors, readers are cautioned not to place undue reliance on these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this release.

Investor Contact:

Jenene ThomasJTC TeamT (US): +1 (833) 475-8247E: aezs@jtcir.com

This advertisement has not loaded yet, but your article continues below.

Sign up to receive daily headline news from the Montreal Gazette, a division of Postmedia Network Inc.

A welcome email is on its way. If you don't see it, please check your junk folder.

The next issue of Montreal Gazette Headline News will soon be in your inbox.

We encountered an issue signing you up. Please try again

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notificationsyou will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Original post:

Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program - Montreal Gazette

Most Toxic Food in the World? Farmed Salmon. – The Epoch Times

It may even be your favorite dish to order when you eat out. Many people think its a heathy choice when they buy it or order out, but thats no longer true.

Fish are an important part of the ecosystem and the human diet. Unfortunately, overfishing has depleted many fish stocks, and the proposed solution fish farming is creating far more problems than it solves. Not only are fish farms polluting the aquatic environment and spreading disease to wild fish, farmed fish are also an inferior food source, in part by providing fewer healthy nutrients; and in part by containing more toxins, which readily accumulate in fat.

Salmon is perhaps the most prominent example of how fish farming has led us astray. Food testing reveals farmed salmon is one of the most toxic foods in the world, having more in common with junk food than health food.[1][2] Studies highlighting the seriousness of the problem date back more than a decade and include:

In 2018, researchers warned[9][10] that farmed Atlantic salmon sold in the U.S. and U.K. may also contain polybrominated diphenyl ethers (PBDEs), toxic POPs that have been restricted or banned in the U.S. and many European countries due to their toxic influence on child development.[11] As reported by The Star,[12] [A] new study by the University of Pittsburgh has found evidence of PBDEs in food fed to farmed salmon even in those in supposedly PBDE-free environments.

PBDEs are a class of chemicals that for years were used as flame retardants, and while restrictions were placed on some of the chemicals in this class in 2004, they can still be found in older products and in the environment. China, Thailand and Vietnam three areas that process significant amounts of electronic waste are known to have higher levels of PBDEs in the environment.

In more recent years, flame retardant pollution has raised serious concern, as these chemicals build up in the environment over time and are in many areas now found in both ground water and open waters.

Health risks associated with these chemicals, including PBDEs, include infertility, birth defects, neurodevelopmental delays,[13] reduced IQ,[14] hormone disruptions[15] and cancer. In fact, flame retardant chemicals have been identified as one of 17 high priority chemical groups that should be avoided to reduce breast cancer.[16]

Youre probably familiar with the saying that you are what you eat. However, a key take-home message here is that you are what your food eats. In other words, whatever the animal you eat consumed, you consume also, which means you really need to know the source of the animals feed as well. In the case of farmed fish, toxins in the fish feed and environmental concentrations of the chemicals have been identified as the two primary culprits.

According to the authors, when the fish are raised in areas with high PBDE concentrations in the water, the feed becomes a relatively minor contributor. In PBDE-free waters, on the other hand, elevated concentrations of these toxins in the feed may be high enough to end up on your plate. As noted by lead author Carla Ng, assistant professor of civil and environmental engineering at the University of Pittsburghs Swanson School of Engineering:[17]

[I]n otherwise clean and well-regulated environments, contaminated feed can be thousands of times more significant than the location of the farm for determining the PBDE content of salmon fillets The international food trade system is becoming increasingly global in nature and this applies to animal feed as well.

Fish farming operations may import their feed or feed ingredients from a number of countries, including those without advanced food safety regulations. The United States and much of Europe banned several PBDEs in 2004 because of environmental and public health concerns. PBDEs can act as endocrine disruptors and cause developmental effects. Children are particularly vulnerable.

One of the main ingredients in farmed salmon feed is fatty fish such as eel, selected for their high protein and fat content. The problem is, many toxins readily bind to fat, and the fish feed industry is using fish deemed unfit for human consumption due to elevated toxicity. As you might expect, when the fish used in fish feed contain toxic levels of pollutants, they get incorporated into the feed pellets.

One significant source of fish for farmed salmon feed is the Baltic Sea, which is well-known for its elevated pollution levels. Nine industrialized countries dump their toxic waste into this closed body of water, which has rendered many Baltic Sea fish inedible. In Sweden, fish mongers are actually required to warn patrons about the potential toxicity of Baltic fish.

According to government recommendations, you should not eat fatty fish like herring more than once a week, and if youre pregnant, fish from the Baltic should be avoided altogether. As mentioned by Ng, fish farms may also import their feed, or individual ingredients from other countries with lax regulations and significant pollution.

Some of the toxicity also stems from the manufacturing process of the feed pellets. The fatty fish are first cooked, resulting in protein meal and oil. While the oil has high levels of dioxins and PCBs, a chemical called ethoxyquin is added to the protein powder as an antioxidant, which further adds to the toxicity of the final product. Ethoxyquin, developed as a pesticide by Monsanto in the 1950s, is one of the best kept secrets of the fish food industry and one of the most toxic.

The use of ethoxyquin is strictly regulated on fruits, vegetables and in meat, but not in fish, because it was never intended for such use. Fish feed manufacturers never informed health authorities they were using this pesticide as a preservative to prevent the fats from oxidizing and going rancid, so its presence in farmed fish was never addressed.

Disturbingly, testing reveals farmed fish can contain levels of ethoxyquin that are up to 20 times higher than the level allowed in fruits, vegetables and meats.

Whats more, the effects of this chemical on human health have never been established. The only research done on ethoxyquin and human health was a thesis by Victoria Bohne, a former researcher in Norway who discovered ethoxyquin can cross the blood-brain barrier and may have carcinogenic effects. Bohne was pressured to leave her research job after attempts were made to falsify and downplay her findings.

Salmon is one fish species looked to as an indicator of environmental conditions, and salmon have become increasingly toxic. While farmed salmon is by far the worst, even wild salmon can contain unwanted pollutants. In a study[18] of salmon found in Puget Sound, researchers discovered 40 contaminants, including drugs, in the flesh of the fish.

Some of the drugs were found at levels known to interfere with growth, reproduction and behavior. No one knows exactly how this chemical cocktail affects the fish, especially as they are exposed in combination. In all, the study found 81 of 151 contaminants tested for in Puget Sound off the coast of Washington.

Aside from toxins already mentioned above, such as PCBs, PBDEs and other POPs, researchers have also found a long line of pesticides including the long-banned DDT at concerning levels in fish off the coast of California.[19] And despite the Clean Water Act, enacted nearly 40 years ago, there are areas of the U.S. where the water is so contaminated with mercury that residents are warned to refrain from eating any locally caught fish.[20]

The fish you eat may also come with a side order of microplastic;[21] in 2016 as 13 metric tons of plastic was entering the waterways every year. Once consumed, microplastic particles tend to remain in the body and accumulate, becoming increasingly concentrated in the bodies of animals higher up the food chain.

Scientists are still unsure of the effect this may have on those who eat the fish, but common sense would suggest it might not be entirely harmless, considering the fact that microplastic fibers soak up toxins like a sponge, concentrating PCBs, flame retardant chemicals, pesticides and anything else found in the water.

Evidence also suggests these microscopic particles can cross cellular membranes, causing damage and inflammation inside the cell. According to a 2016 report[22] by the British Department for Environment Food and Rural Affairs [DEFRA], microplastics have been found in a wide variety of sea creatures, from zooplankton to whales and everything in between.

According to this report, microplastics are present in seafood sold for human consumption, including mussels in North Sea mussel farms and oysters from the Atlantic.

Eating six oysters could introduce about 50 plastic microbeads into your body and, according to DEFRA, this kind of contamination may indeed pose a threat to food safety. Other studies have found one-third of the fish caught in the English Channel contain microbeads, as do 83 percent of scampi sold in the U.K.[23]

As mentioned at the beginning, farmed salmon is also nutritionally less desirable than wild, which actually ties in with its toxicity. One significant nutritional difference is the fat content. Wild salmon contains about 5 to 7 percent fat, whereas the farmed variety can contain anywhere from 14.5 to 34 percent.

This elevated fat content is a direct result of the processed high-fat feed that farmed salmon are given, and since they contain more fat, they also accumulate higher amounts of toxins. Even when raised in similarly contaminated conditions, farmed salmon will absorb more toxins than the wild fish because of this.

But farmed salmon doesnt just contain more fat overall; another nutritional travesty is its radically skewed ratios of omega-3 to omega-6 fats.[24] Half a fillet of wild Atlantic salmon contains about 3,996 milligrams (mg) of omega-3 and 341 mg of omega-6.[25] Half a fillet of farmed salmon from the Atlantic contains just a bit more omega-3 4,961 mg but an astounding 1,944 mg of omega-6;[26] more than 5.5 times more than wild salmon.

While you need both omega-3 and omega-6 fats, the ratio between the two is important and should ideally be about 1-to-1. The standard American diet is already heavily skewed toward omega-6, thanks to the prevalence of processed foods, and with farmed salmon, that unhealthy imbalance is further magnified rather than corrected.

A 2011 Norwegian report on farmed fish feed ingredients[27] titled Todays and Tomorrows Feed Ingredients in Norwegian Aquaculture talks about the negative impacts of the antinutritional factors of plant proteins and other additives in the feed.

Some of the most common ingredients in farmed fish feed include soybeans, rapeseed/canola oil, sunflower meal and oil, corn gluten meal from corn grains, wheat gluten, pulses (dry, edible seeds of field peas and faba beans), palm oil, and peanut meal and oil none of which are natural wild salmon foods.

However, as the Food and Agriculture Organization of the United Nations (FAO) explains,[28] Atlantic farmed salmon feeds can also contain animal by-products from poultry, meat meal, blood and hydrolyzed feathers. Additives such as enzymes, crustacean products (to color the salmon flesh), vitamins and selenium are also added and again, none these are ingredients that any wild salmon has ever encountered and all are about as far from a species-appropriate diet as you can get.

By 2016 more than half the fish Americans were eating came from fish farms.[29] Aquaculture promotes itself as a sustainable solution to overfishing, but when you consider it takes 1.5 to 8 kilograms (3.3 to 17.6 pounds) of wild fish to produce a single kilogram (2.2 pounds) of farmed salmon, you start to realize there are significant holes in that claim. In reality, the aquaculture industry is actually contributing heavily to the depletion of wild fish stocks rather than saving it.[30]

A salmon farm can hold upward of 2 million salmon in a relatively small amount of space. As with land-based factory farms where animals are kept in crowded conditions, fish farms are plagued with diseases that spread rapidly among the stressed fish. Sea lice, pancreas disease and infectious salmon anemia virus have spread all across Norway, yet consumers have not been informed of these fish pandemics, and sale of diseased fish continues unabated.

To stave off disease-causing pests, a number of dangerous pesticides are used, including one known to have neurotoxic effects. Workers who apply this pesticide must wear full protective clothing, yet these chemicals are dumped right into open water, where it spreads with local currents.

The pesticides used have been shown to affect fish DNA, causing genetic effects. Estimates suggest about half of all farmed cod, for example, are deformed due to genetic mutations. Whats worse, female cod that escape from farms are known to mate with wild cod, spreading the genetic mutations and deformities into the wild population.

Its become quite clear that fish farms are not a viable solution to overfishing. If anything, theyre making matters worse, destroying the marine ecosystem at a far more rapid clip. Consumers also need to be aware that some farmed salmon may also be genetically engineered (GE).

AquaBounty salmon, engineered to grow twice as fast as typical farm-raised salmon, received U.S. Food and Drug Administration approval in November 2015; it hit grocery store shelves and restaurants in 2021.[31] Originally, it had been scheduled for marketing in 2020, but was delayed due to the COVID pandemic.

Crazy enough, the FDA is not regulating Aquabountys salmon as food. It chose to review it as a drug. All GE animals, it turns out, starting with this GE salmon, will be regulated under the new animal drug provisions of the Federal Food, Drug and Cosmetic Act, because the recombinant DNA (rDNA) construct introduced into the animal meets the definition of a drug.

Interestingly, when AquaBounty announced that the GE fish was coming to market, they told The Associated Press that it would be going to restaurants and away-from-dining services where labeling as genetically engineered is not required.[32] Yet the reason the FDA gave for not requiring the fish to carry some form of GE label is that its nutritionally equivalent to conventional farm-raised Atlantic salmon.

The unnatural growth rate was achieved by inserting the DNA from two other fish, a growth-promoting gene from a Chinook salmon and a promoter gene from the eel-like ocean pout. This genetic tweaking results in fish with a chronic, continuous release of growth hormone. While a typical salmon might take up to 36 months to reach market size (and grow only in spurts during warm weather), AquaAdvantage GM salmon are ready for market in just 16 to 18 months.

The fish are being grown on land and have several other supposed safeguards in place to prevent both escape and breeding with wild populations but, in nature, nothing is foolproof. This became readily evident in 2017, when thousands of land-based Atlantic salmon escaped when the pens were broken asunder by a passing storm, creating what regulators called an environmental nightmare.[33]

So, whats the answer? Unfortunately, the vast majority of fish even when wild caught is frequently too contaminated to eat on a frequent basis. Most major waterways in the world are contaminated with mercury, heavy metals, POPs and agricultural chemicals.

This is why, as a general rule, I no longer recommend eating fish on a regular basis. There are exceptions, however. One is authentic wild-caught Alaskan salmon, the nutritional benefits of which I believe still outweigh any potential contamination. The risk of wild Alaskan salmon accumulating high amounts of mercury and other toxins is reduced because of its short life cycle, which is only about three years.

Alaskan salmon (not to be confused with Atlantic salmon) is not allowed to be farmed, and is therefore always wild-caught. Canned salmon labeled Alaskan salmon is a less expensive alternative to salmon fillets. Remember that wild salmon is quite lean, so the fat marks those white stripes you see in the meat are on the thin side.

If a fish is pale pink with wide fat marks, the salmon is likely farmed. Avoid Atlantic salmon, as salmon bearing this label are almost always farmed.

Another exception is smaller fish with short lifecycles, which also tend to be better alternatives in terms of fat content, such as sardines and anchovies. With their low contamination risk and higher nutritional value, they are a win-win alternative. Other good choices include herring and fish roe (caviar), which is full of important phospholipids that nourish your mitochondrial membranes.

Originally published Feb 2 2022 on Mercola.com

Views expressed in this article are the opinions of the author and do not necessarily reflect the views of The Epoch Times.

Read more:

Most Toxic Food in the World? Farmed Salmon. - The Epoch Times

Ask the doctor: Should my granddaughter have her adenoids removed? – Independent.ie

Question: My three-year-old granddaughter lives in another European country and has been sick a lot lately. The doctor there has suggested that she have her adenoids removed but my son is against it as he wants more information before they get it done and there is a bit of a language barrier. She is sick a lot with viruses but arent all kids? Why would a child have their adenoids out, what is the impact of it and should he go ahead or wait until she grows out of whatever it is?

Dr Grant replies: Most surgeons opt for a conservative approach or to watch and wait. In other words, they will not perform any surgery unless it is absolutely necessary or in the best interest of the child. Both tonsillectomy (removal of the tonsils) and adenoidectomy (removal of the adenoids) are among the most common surgical procedures performed in children. The decision to undergo surgery depends on the childs specific complaint, the surgeons recommendations and the guardians of the child.

Each country will vary on their guidelines and criteria, as will surgeons depending on where they currently work and where they trained in the past. The two main indications for tonsillectomy and/or adenoidectomy are upper airway obstruction and recurrent infection.

The general trend has seen a decline in the number of tonsillectomies and adenoidectomies performed for infectious indications, while the number performed for obstructive indications has increased. Expanding more on the upper airway obstruction, Obstructive Sleep Apnoea (OSA) is common in children and can lead to chronic snoring, poor sleep and in the longterm, poor overall growth and performance.

During the first few hours of sleep, children release most of the growth hormone allowing their bones to grow and if their sleep is chronically disturbed due to snoring and breath holding, it may affect overall growth. Poor sleep, we all know, leads to irritability and fatigue and adversely affects your cognitive abilities.

Long-term sleep apnoea can put additional, unnecessary strain on the cardiovascular system at night when the body is supposed to be healing and repairing. When it comes to recurrent infections, the benefits of tonsillectomy (with or without adenoidectomy) in children with recurrent throat infections (i.e. tonsillitis, pharyngitis, tonsillopharyngitis) depends on the frequency and severity of previous episodes.

For example, one criteria for surgery states the child should have +3 episodes in each of three years, +5 episodes in each of two years, or +7 episodes in one year. My own 11-year-old child had up to four severe episodes of tonsillitis per year for a number of years, and was truly miserable each time. It takes up to one week to fully recover and as a parent, it is difficult seeing your child in pain, but we held off and my child has been symptom-free for over four years now. Adenoidectomy is considered when the adenoids are enlarged (hypertrophied) and/or infected resulting in nasal obstruction, rhinosinusitis, eustachian tube dysfunction and otitis media.

Nasal obstruction may lead to chronic mouth breathing, hypo-nasal speech, and impaired olfaction (sense of smell). Severe obstruction due to adenoidal hypertrophy is an absolute indication for surgery. In summary, the decision should be made on a case-by-case basis after weighing the benefits and risks of the surgery as well as the values and preferences of the family and child.

Dr Jennifer Grant is a GP with Beacon HealthCheck

Read more from the original source:

Ask the doctor: Should my granddaughter have her adenoids removed? - Independent.ie

Hydroxyprogesterone Market Emerging Trends, Strong Application Scope, Size, Status, Analysis and Forecast to 2030 Indian Defence News – Indian…

Hydroxyprogesterone Market Report Coverage: Key Growth Factors & Challenges, Segmentation & Regional Outlook, Top Industry Trends & Opportunities, Competition Analysis, COVID-19 Impact Analysis & Projected Recovery, and Market Sizing & Forecast.

Latest launched research on Global Hydroxyprogesterone Market, it provides detailed analysis with presentable graphs, charts and tables. This report covers an in depth study of the Hydroxyprogesterone Market size, growth, and share, trends, consumption, segments, application and Forecast 2030. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Hydroxyprogesterone Market. This report has been prepared by experienced and knowledgeable market analysts and researchers. Each section of the research study is specially prepared to explore key aspects of the global Hydroxyprogesterone Market. Buyers of the report will have access to accurate PESTLE, SWOT and other types of analysis on the global Hydroxyprogesterone market. Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries.

Major Key players profiled in the report include:AMAG Pharmaceuticals, Naari Ag, Mcguff Pharmaceuticals Inc, ANI Pharmaceuticals, Inc., Diosynth Bv, Mylan Institutional, Steroid Spa, Aspen Oss B.V., Antibioticos Spa, Schering Ag, Sun Pharmaceutical, Zhejiang Xianju Pharmaceutical, Symbiotec Pharmalab, Upjohn Co

Download Free Sample PDF including COVID19 Impact Analysis, full TOC, Tables and [emailprotected] https://marketstrides.com/request-sample/hydroxyprogesterone-market

Dont miss the trading opportunities on Hydroxyprogesterone Market. Talk to our analyst and gain key industry insights that will help your business grow as you create PDF sample reports.

Segmental Analysis:The report has classified the global Hydroxyprogesterone market into segments including product type and application. Every segment is evaluated based on share and growth rate. Besides, the analysts have studied the potential regions that may prove rewarding for the Hydroxyprogesterone manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, there by helping market players to gain deep insights into the overall Hydroxyprogesterone industry.

Market split by Type, can be divided into:Oral, Injection

Market split by Application, can be divided into:Hospitals, Clinics

Share your budget and Get Exclusive Discount @https://marketstrides.com/check-discount/hydroxyprogesterone-market

The authors of the report have analyzed both developing and developed regions considered for the research and analysis of the global Hydroxyprogesterone market. The regional analysis section of the report provides an extensive research study on different regional and country-wise Hydroxyprogesterone industry to help players plan effective expansion strategies.

Regions Covered in the Global Hydroxyprogesterone Market: North America (U.S., Canada) Europe (U.K., Germany, France, Italy) Asia Pacific (China, India, Japan, Singapore, Malaysia) Latin America (Brazil, Mexico) Middle East & Africa (Kuwait, Saudi Arabia Egypt)

Years Considered to Estimate the Market Size:History Year: 2019-2020Base Year: 2021Estimated Year: 2022Forecast Year: 2022-2030

What market dynamics does this report cover? The report shares key insights on:

It helps companies make strategic decisions

About Us:

Market Strides is a Global aggregator and publisher of Market intelligence development reports, equity reports, database directories, and economic reports. Our repository is diverse, spanning virtually every industrial sector and even more every category and sub-category within the industry.

Our pre-onboarding strategy for publishers is perhaps, what makes us stand out in the market space. Publishers & their market Share, reports are meticulously validated by our in-house panel of consultants, prior to a feature on our website. These in-house panel of consultants are also in charge of ensuring that our website features the most updated reports only.

Have Any Query? Ask Our Experts

Market Strides have team of professionals that assist you in many advanced industry specific trends, content and tests different strategies and implements the most productive one for the business.

For more information, Email [emailprotected]

Contact Us: +1 856 677 8909 (US)

Follow us on Social Media:

Trending Reports:https://www.digitaljournal.com/pr/colposcopes-market-analysis-2022-with-detailed-competitive-outlook-by-2026-prominent-players-cooper-surgical-edan-instruments-inchttps://marketstrides.com/report/middle-east-and-africa-growth-hormone-deficiency-therapy-markethttps://marketstrides.com/report/capacitors-for-medical-electronics-markethttps://marketstrides.com/report/text-analytics-market

Read the original:

Hydroxyprogesterone Market Emerging Trends, Strong Application Scope, Size, Status, Analysis and Forecast to 2030 Indian Defence News - Indian...